TY - JOUR
T1 - Infection control practices in patients with hematological malignancies and multidrug-resistant organisms
T2 - Special considerations and challenges
AU - Ariza-Heredia, Ella J.
AU - Chemaly, Roy F.
N1 - Publisher Copyright:
© 2014 Elsevier Inc.
PY - 2014/9/1
Y1 - 2014/9/1
N2 - Infectious complications contribute greatly to morbidity and mortality in patients with hematological malignancies. As these patients undergo prolonged chemotherapy and are in frequent contact with health care settings, they are at high risk for nosocomial and health care-associated infections. This long-term relationship with the hospital setting represents a major opportunity for infection prevention. In this review, we describe several infection control strategies that are currently used to reduce the transmission of hospital-acquired infections in patients with hematological malignancies, particularly infections with multidrug-resistant organisms.
AB - Infectious complications contribute greatly to morbidity and mortality in patients with hematological malignancies. As these patients undergo prolonged chemotherapy and are in frequent contact with health care settings, they are at high risk for nosocomial and health care-associated infections. This long-term relationship with the hospital setting represents a major opportunity for infection prevention. In this review, we describe several infection control strategies that are currently used to reduce the transmission of hospital-acquired infections in patients with hematological malignancies, particularly infections with multidrug-resistant organisms.
KW - Health-care associated infections
KW - Hematological malignancies
KW - Infection control
KW - Multidrug-resistant organisms
KW - prevention
UR - http://www.scopus.com/inward/record.url?scp=84939430650&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84939430650&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2014.06.021
DO - 10.1016/j.clml.2014.06.021
M3 - Article
C2 - 25486947
AN - SCOPUS:84939430650
SN - 2152-2650
VL - 14
SP - S104-S110
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
ER -